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Introduction
Atrial fibrillation (AF) is triggered by ectopic beating of the 
pulmonary vein (PV), and catheter-based pulmonary vein iso-
lation (PVI) using radiofrequency is accepted to be effective 
for treatment of patients in whom AF is refractory to anti-ar-
rhythmic drugs.1,2) The preferred ablation strategy features 
electrical isolation of the PV by creation of circumferential le-
sions around the right and left PV ostia.3) Although three-di-
mensional (3D) mapping systems are routinely used for cathe-
ter-based PVI, point-by-point ablation remains complex and 
time-consuming, requiring a high level of technical compe-
tence. Such technical complexity and the need to visualize the 
circular mapping and ablation catheters in real time, means 
that many centers perform only one or two procedures daily, 
and patients endure long-term procedural discomfort and are 
exposed to the risks associated with general anesthesia. More 
importantly, patients are subjected to significant levels of radia-
tion (shared to some extent by the operators).4-7) The adverse 
effects of radiation exposure during the catheter ablation are 
well documented in medical literature.8,9) To address such tech-
nical difficulties; and to render the procedure simpler, shorter, 
and safer; multielectrode catheters enabling simultaneous map-
ping and ablation have been developed. Such catheters allow an 
operator to create lesions over much of the circumference of 
each PV via a single radiofrequency (RF) application, without 
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Objectives: In patients with atrial fibrillation (AF), the success rate of pulmonary vein isolation 
procedure has improved with advances in three-dimensional mapping systems but procedure re-
mains complex and time-consuming. AF ablation using a multielectrode catheters enabling both 
mapping and ablation have been developed to address the technical difficulties. Our objective was 
to systematically review current knowledge on the efficacy and procedural durability of AF ablation 
using a multielectrode catheter (MEA), compared to conventional pulmonary vein isolation (CPVI). 
Methods: We systematically searched PubMed, EMBASE, Cochrane, and Korean domestic databas-
es for studies on MEA and CPVI. Results: Our meta-analysis showed that procedural time [stan-
dardized mean difference (SMD)=-1.17, 95% confidence interval (CI): -1.67, -0.67] and fluoroscopic 
time (SMD=-0.64, 95% CI: -1.04, -0.24) were significantly shorter in MEA. The risk of AF recurrence 
[relative risk (RR)=0.85, 95% CI: 0.76, 0.94] was significantly lower and repeat procedures (RR=0.73, 
95% CI: 0.53, 1.00) tended to be lower in MEA without statistical significance. No significant be-
tween-treatment difference in complication rates was evident with a trend toward higher complica-
tion rate in MEA (RR=1.04, 95% CI: 0.55, 1.93). Conclusion: In patients undergoing catheter abla-
tion to treat AF, the efficacies of MEA and CPVI were comparable in terms of acute procedural 
success and repeat procedures. However, MEA afforded the benefit of reduced procedure-related 
time, including procedural time, fluoroscopic time, and radiofrequency application time and lower 
AF recurrence. MEA was associated with a slightly higher risk of thromboembolism, but nonethe-
less afforded patient benefits, when skilled physicians carefully performed all procedures.
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having to change position. Thus, procedural time is reduced; 
the need for fluoroscopy minimized; procedural efficacy and 
safety maintained or improved; and AF ablation rendered more 
accessible, associated with shorter surgical learning curves.10)
To date, only three systematic reviews on the use of catheter-
based ablation to treat AF have appeared, of which two com-
pared catheter ablation with medical treatment.11,12) One re-
view assessed the safety and efficacy of AF ablation using 
phased RF energy and multielectrode catheters, but presented 
only quantitative acute procedural and 6/12 month success 
rates.13)
No previous study has systematically reviewed the efficacy 
and safety of multielectrode catheter ablation (MEA) com-
pared to conventional PV isolation (CPVI). Therefore, the ob-
jective of our present study was to systematically review the ef-
ficacy and procedural durability of AF ablation using 
multielectrode catheters (the MEA procedure), and CPVI.
Methods
We systematically reviewed available data using a predeter-
mined protocol established by reference to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis statement 
(http://www.prisma-statement.org/).
Search strategy
To identify and retrieve all relevant literature describing the 
outcomes of AF patients treated via MEA, we searched PubMed, 
EMBASE, Cochrane, and four Korean domestic databases in 
April 2015. Search terms included both keywords and corre-
sponding Medical Subject Headings; thus “atrial fibrillation” 
AND “multielectrode radiofrequency ablation” AND “conven-
tional point-by-point ablation”. Inclusion criteria were: 1) the 
work was an original article on AF patients; 2) the research de-
sign was controlled; 3) MEA was compared with conventional 
ablation using 3D mapping methods; and, 4) the language of 
publication was English or Korean. Exclusion criteria were: 1) 
research on conditions other than paroxysmal or persistent 
AF; 2) treatment with other than MEA; 3) comparison of 
MEA with conditions other than CPVI; 4) non-reporting of 
MEA outcomes reported; 5) non-reporting of MEA efficacy; 
6) a case series or a case report; 7) an animal study or an ab-
stract-only publication; and, 8) an evidence level lower than 
two upon analysis of bias risk. Secondary texts were identified 
via manual review of the reference lists.
Study selection and assessment of bias risk
Two investigators independently assessed publications con-
sidered to be eligible for inclusion at the title and/or abstract 
level. Full-text reviews were conducted if it was difficult to as-
certain from the abstract whether the article met our inclu-
sion/exclusion criteria. The risk of bias in each study was eval-
uated by two independent investigators using the Scottish 
Intercollegiate Guideline Network checklist. The questions 
posed explored concealment of patient allocation and the 
presence of other potential sources of bias.
Data collection and analysis
A standardized data extraction form was used to extract 
outcomes of interest and two investigators independently ex-
tracted data from selected full-text articles using this form 
(which reinforced the inclusion and exclusion criteria). Out-
come variables included procedural, fluoroscopic time, and RF 
application times, acute success rates upon treatment of pa-
tients, AF recurrence, need for repeat procedures and compli-
cations, in an effort to evaluate the procedural durability and 
efficacy of MEA compared to CPVI. If the two reviewers dis-
agreed on any topic, the disagreement was resolved by consul-
tation. We performed a meta-analysis to estimate pooled esti-
mates of standardized mean differences (SMDs) or relative 
risks (RRs) among outcome variables. Pooled estimates were 
obtained using fixed-effect or random-effects models, depend-
ing on the extent of heterogeneity evident among studies. Het-
erogeneity was assessed by derivation of Q statistics and quan-
tified using Higgin’s I2 statistic. Also, all of sensitivity analysis, 
subgroup analysis, and meta-regression were used to assess 
Fig. 1. Flowchart showing search and selection of studies for re-
view.
Records identified through database search
(n=337, Pubmed 78, EMBASE 233, Cochrane 16, Domestic 10)
Additional records identified
through hand-searching (n=4)
Records duplicated (n=56)
Failed to meet inclusion criteria 
(n=270)
Excluded due to quality 
assessment (lever of evidence 
2-below) (n=0)
Records after duplicates 
removed (n=285)
Records selected for detailed 
full-text review (n=15)
Studies included in 
final analysis (n=15)
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heterogeneity. Forest plots and pooled estimates were pro-
duced using Review Manager version 5.2 (the Cochrane Col-
laboration). Funnel plot and meta-regression analysis were 
performed with the aid of Stata version 12.0 (Stata Corpora-
tion, College Station, TX, USA).
Results
Literature search and study characteristics
Of the 337 articles reviewed, 15 including 2732 patients sat-
isfied our predetermined inclusion criteria;10,14-27) these includ-
ed seven randomized controlled trials15,17,18,21,24-26) and eight 
non-randomized comparative studies10,14,16,19,20,22,23,27) (Fig. 1). 
Study characteristics are listed in Table 1. Overall, 1437 pa-
tients underwent MEA procedures, and 1295 patients CPVI, 
to treat paroxysmal or persistent AF. Of the 15 selected studies, 
7 dealt with paroxysmal AF patients and 8 included those with 
paroxysmal or persistent AF.
Procedural outcomes
Procedural and fluoroscopic times
The total MEA procedural time was 45 min less than that of 
CPVI [SMD=-1.17, 95% confidence interval (CI): -1.67, -0.67, 
p<0.00001] (Fig. 2). The total fluoroscopic time was also sig-
nificantly less (by 7.16 min) when MEA rather than CPVI was 
performed (SMD=-0.64, 95% CI: -1.04, -0.24, p=0.002). The 
MEA RF application time was 11.96 min shorter than that as-
sociated with CPVI, and this difference was significant 
(SMD=-0.70, 95% CI: -1.26, -0.14, p=0.01).
Table 2 shows our subgroup analysis of the pooled estimates 
of SMDs in procedural time between MEA and CPVI strati-
fied by study design, AF type, and catheter type. In terms of 
study design, the MEA procedural time was significantly less 
than that of CPVI in both randomized (SMD=-1.17, 95% CI: 
-1.63, -0.71, p<0.00001) and non-randomized controlled trials 
(SMD=-1.16, 95% CI: -2.07, -0.25, p=0.01), and the pooled 
SMD was larger for Randomized Controlled Trials. In terms of 
AF type, MEA was associated with a procedural time signifi-
cantly shorter than required for CPVI (SMD=-0.97, 95% CI: 
-1.54, -0.40, p=0.0009) in patients with paroxysmal AF, but not 
in those with persistent AF (SMD=0.24, 95% CI: -0.12, 0.60, 
p=0.19). The MEA procedural time was significantly shorter 
than that of CPVI when either catheter type was used for mul-
tielectrode ablation. The catheters used were a duty-cycled 
multipolar ablation catheter (SMD=-1.15, 95% CI: -1.67, -0.62, 
p<0.0001) and a high-density mesh ablator catheter (SMD= 
-1.54, 95% CI: -2.11, -0.97, p<0.00001).
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Clinical outcomes
Ten studies10,14-19,21-23) reported the success rates of acute pro-
cedures in terms of complete PV isolation immediately after 
ablation. No significant between-treatment difference in acute 
procedural success rate was evident (RR=0.99, 95% CI: 0.97, 
1.01, p=0.35). After ablation, the risk of AF recurrence was 
lower if MEA had been employed (RR=0.85, 95% CI: 0.76, 
0.94, p=0.002) (Fig. 3) with statistical significance from twelve 
studies10,14-18,22-27) reporting AF recurrence. Also, the number of 
repeat procedures performed after initial ablation that did not 
completely isolate the PV was somewhat less after MEA than 
CPVI (RR=0.73, 95% CI: 0.53, 1.00, p=0.05), but the differ-
ence was not significant.
Table 3 presents our subgroup analysis results for AF recur-
rence stratified by follow-up period, study design, AF type, 
and catheter type used during MEA. AF recurred less often af-
ter MEA in studies with shorter follow-up durations (less than 
6 months; RR=0.69, 95% CI: 0.45, 1.06, p=0.09, and 6–12 
months; RR=0.80, 95% CI: 0.53, 1.19, p=0.27). Also, MEA was 
associated with a reduced AF recurrence more than 1 year af-
ter the procedure (RR=0.87, 95% CI: 0.78, 0.97, p=0.01) and 
the difference was statistically significant. Meta-regression of 
the RRs for AF recurrence after MEA vs. CPVI in terms of fol-
low-up duration showed a tendency toward establishment of a 
slightly positive linear relationship between the RR and follow-
up duration without significance (β=0.005, 95% CI: -0.007, 
0.017, p=0.395) (Fig. 4).
Table 2. Subgroup analysis on the mean difference of procedure time between MEA and CPVI
Sub-group
No. 
of study
No. of patients Std. mean difference 
(95% CI)MEA CPVI
Total 14 1426 1292 -1.17 (-1.68, -0.67)*
Sensitivity analysis† 12 1181 1045 -1.48 (-1.98, -0.98)*
Study design RCT 7 568 604 -1.17 (-1.63, -0.71)*
Non randomized study 7 858 688 -1.16 (-2.07, -0.25)*
AF type Paroxysmal AF 8 561 635 -0.97 (-1.54, -0.40)*
Persistent AF 1 66 56 0.24 (-0.12, 0.60)
Catheter type Duty-cycled multipolar ablation catheter 14 1388 1266 -1.15 (-1.67, -0.62)*
High-density mesh ablator catheter 1 38 26 -1.54 (-2.11, -0.97)*
*Pooled estimates are from random-effects model, †Sensitivity analysis was performed by excluding extreme studies. AF: atrial fi-
brillation, MEA: multielectrode catheter ablation, CPVI: conventional pulmonary vein isolation, CI: confidence interval, RCT: ran-
domized controlled trial
Fig. 2. Forest plot for standardized mean difference (SMD) for procedure time between multielectrode catheter ablation (MEA) and 
conventional pulmonary vein isolation (CPVI). CI: confidence interval, SD: standard deviation.  
Study or subgroup
MEA CPVI
Weight
Std. mean difference Std. mean difference
Mean SD Total Mean SD Total IV, random, 95% CI IV, random, 95% CI
Beukema et al.22) 138 35 89 175 56 96 6.8% -0.78 [-1.08, -0.48]
Bittner et al.17) 171 40 40 224 27 40 6.5% -1.54 [-2.04, -1.04]
Bulava et al.15) 107 31 51 208 46 51 6.5% -2.56 [-3.08, -2.03]
Bulava and Haniš23) 105 30 79 174 40 158 6.8% -1.86 [-2.18, -1.54]
Choo et al.18) 168 41 38 252 60 71 6.6% -1.54 [-1.98, -1.09]
De Greef et al.24) 121 41 79 169 43 82 6.8% -1.14 [-1.47, -0.80]
Gaita et al.21) 127 53 36 123 45 36 6.6% 0.08 [-0.38, 0.54]
Gal et al.25) 134 39 230 178 49 230 6.9% -0.99 [-1.19, -0.80]
Khaykin et al.10) 125 25 31 135 26 19 6.4% -0.39 [-0.96, 0.19]
McCready et al.26) 140 43 94 167 42 94 6.8% -0.63 [-0.93, -0.34]
Herrera Siklódy et al.19) 124 32 24 198 50 27 6.3% -1.71 [-2.36, -1.06]
Spitzer et al.27) 67 18 388 142 35 151 6.9% -3.12 [-3.39, -2.86]
Steinwender et al.14) 175 35 38 235 43 26 6.4% -1.54 [-2.11, -0.97]
Tivig et al.16)-Paroxysaml 128 38 143 134 43 155 6.9% -0.15 [-0.37, 0.08]
Tivig et al.16)-Persistent 171 39 66 161 44 56 6.8% 0.24 [-0.12, 0.60]
Total (95% CI) 1426 1292 100.0% -1.17 [-1.67, -0.67]
Heterogeneity: Tau2=0.94; Chi2 =454.34, df=14 (p<0.00001); I2=97% 
Test for overall effect: Z=4.56 (p<0.00001)
-4 -2 0 2 4
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Complications
Reported complications associated with PV isolation via 
catheter ablation included embolisms, pericardial effusion, 
stroke, tamponade, pulmonary vein puncture, transient isch-
emic attack, femoral hematoma, and pseudoaneurysms. No 
significant between-treatment difference in the frequency of 
occurrence of any complication was evident, but a trend to-
ward a higher complication rate after MEA was apparent 
(RR=1.04, 95% CI: 0.55, 1.93, p=0.91) (Fig. 5). Eight studies 
17,19-21,24-27) reported thromboembolic complications, the most 
frequent and potentially devastating. Of eight relevant studies, 
three19,21,26) reported thromboembolic events in the first 1–2 
days after the procedure and the other five17,20,24,25,27) gave fol-
low-up results at more than 6 months up to 3 years. The risk of 
thromboembolic events tended to be slightly lower after MEA 
(RR=0.99, 95% CI: 0.23, 4.19, p=0.99) at follow-up times of 
over 6 months, in contrast to a higher incidence (RR=4.84, 
95% CI: 2.04, 11.47, p=0.0003) observed during the acute peri-
od (1–2 days after the procedure) (Supplementary Fig. 1).
Discussion
Our present systematic review and meta-analysis found that 
RF ablation using multielectrode catheters reduced procedural 
Table 3. Subgroup analysis on the RRs of AF recurrence between MEA and CPVI
Sub-group
No. 
of study
No. of patients
RR (95% CI)†
MEA CPVI
Total 14 1205 1088 0.85 (0.76, 0.94)
Follow-up period ≤6 month 3 75 97 0.69 (0.45, 1.06)
>6 month, <1 year 4 140 161 0.80 (0.53, 1.19)
≥1 year 7 990 830 0.87 (0.78, 0.97)*
Study design RCT 7 532 568 0.87 (0.77, 1.00)
Non randomized study 7 673 520 0.81 (0.68, 0.96)*
AF type Paroxysmal AF 8 438 534 0.88 (0.72, 1.07)
Persistent AF 2 30 51 0.93 (0.51, 1.72)
Catheter type Duty-cycled multipolar ablation catheter 13 1168 1062 0.84 (0.76, 0.93)*
High-density mesh ablator catheter 1 37 26 1.17 (0.49, 2.82)
*Statistically significant, †Mantel-Haenszel pooled estimate. AF: atrial fibrillation, MEA: multielectrode catheter ablation, CPVI: con-
ventional pulmonary vein isolation, RR: relative risk, CI: confidence interval, RCT: Randomized Controlled Trial
Fig. 3. Forest plot for relative risk (RR) of AF recurrence between multielectrode catheter ablation (MEA) and conventional pulmonary 
vein isolation (CPVI). CI: confidence interval.
Study or subgroup
MEA CPVI
Weight
Risk ratio           Risk ratio
Events Total Events Total M-H, fixed, 95% CI            M-H, fixed, 95% CI
Beukema et al.22) 14 89 16 96 3.5% 0.94 [0.49, 1.82]
Bittner et al.17) 11 40 13 40 2.9% 0.85 [0.43, 1.66]
Bulava et al.15) 12 51 15 51 3.4% 0.80 [0.42, 1.54]
Bulava and Haniš23) 27 79 44 158 6.6% 1.23 [0.83, 1.82]
Choo et al.18)-Paroxysmal 8 30 22 43 4.1% 0.52 [0.27, 1.01]
Choo et al.18)-Persistent 4 8 21 28 2.1% 0.67 [0.32, 1.38]
De Greef et al.24) 28 79 37 82 8.2% 0.79 [0.54, 1.15]
Gal et al.25) 120 230 125 230 28.2% 0.96 [0.81, 1.14]
Khaykin et al.10) 4 31 6 19 1.7% 0.41 [0.13, 1.26]
McCready et al.26) 38 94 41 94 9.3% 0.93 [0.66, 1.30]
Spitzer et al.27) 139 388 78 151 25.4% 0.69 [0.57, 0.85]
Steinwender et al.14) 10 37 6 26 1.6% 1.17 [0.49, 2.82]
Tivig et al.16)-Paroxysmal 3 27 13 47 2.1% 0.40 [0.13, 1.28]
Tivig et al.16)-Persistent 6 22 4 23 0.9% 1.57 [0.51, 4.82]
 
Total (95% CI)  1205 1088 100.0% 0.85 [0.76, 0.94]
Total events 424 441
Heterogeneity: Chi2 =17.03, df=13 (p=0.20); I2=24% 
Test for overall effect: Z=3.14 (p=0.002)
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times and AF recurrence compared to those of CPVI using 3D 
mapping, but the overall efficacies were in terms of acute pro-
cedural success and the need for repeat procedures were com-
parable. The procedural time was significantly reduced in the 
MEA group, but differed among the studies reviewed. Two 
studies16,21) reported that MEA procedural time was longer 
than that of CPVI, contrary to other studies. Perhaps the sur-
geons performing MEA were at early stages of their learning 
curves, whereas the surgeons performing CPVI were not. The 
result has also shown a similarity in fluoroscopy time and RF 
application time representing longer time in MEA. Some ab-
stracts28-31) reported that the learning curve for use of multi-
electrode catheters was relatively short. Over the first 20 cases, 
procedural, fluoroscopic, and application times decreased by 
33%, 45%, and 21%, respectively; and acute success rates in-
creased with procedure experience. Subgroup analysis by AF 
type showed that all of procedural, fluoroscopic, and RF appli-
cation times during treatment of paroxysmal AF patients were 
shorter when MEA was applied, but, in contrast, procedural 
times for persistent AF patients were longer. Such differences 
between AF type may be attributable to the need to perform 
additional ablation dictated by complex fractionated atrial 
electrograms obtained from the left atrial septum and body, 
performed at the discretion of the operator in patients with 
persistent AF.
The acute success rates were comparably high between 
treatments, being 82–100% in most studies when either MEA 
or CPVI was employed. However, the acute success rate of 79–
93% for persistent AF patients was slightly lower than that for 
paroxysmal AF patients, attributable to the need for additional 
ablation to treat persistent AF, as mentioned above.
The RRs of AF recurrence after MEA and CPVI varied by 
follow-up period, and tended to be lower short-term (≤1 year) 
after MEA, and the difference was significant between MEA 
and CPVI upon longer-term follow-up (>1 year); this tenden-
cy was also captured via meta-regression analysis. Likewise, 
the risk of a need for a repeat procedure was lower after MEA 
than CPVI. Such a finding was expected because the need for 
Fig. 4. Meta-regression for relative risk of AF recurrence on fol-
low-up duration in the study. AF: atrial fibrillation. 
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Fig. 5. Forest plot for the pooled RR of complications between multielectrode catheter ablation (MEA) and conventional pulmonary vein 
isolation (CPVI). RR: relative risk, CI: confidence interval.
Study or subgroup
MEA CPVI
Weight
Risk ratio             Risk ratio
Events Total Events Total M-H, random, 95% CI              M-H, random, 95% CI
Beukema et al.22) 3 89 2 96 7.3% 1.62 [0.28, 9.46]
Bittner et al.17) 1 40 2 40 5.0% 0.50 [0.05, 5.30]
Bulava et al.15) 0 51 0 51 Not estimable
Bulava and Haniš23) 2 79 11 158 8.9% 0.36 [0.08, 1.60]
Choo et al.18)-Combined 2 38 2 71 6.6% 1.87 [0.27, 12.74]
De Greef et al.24) 4 79 5 82 10.2% 0.83 [0.23, 2.98]
Deneke et al.20) 2 11 1 3 6.2% 0.55 [0.07, 4.16]
Gaita et al.21) 14 36 3 36 11.0% 4.67 [1.47, 14.86]
Gal et al.25) 3 230 11 230 10.3% 0.27 [0.08, 0.96]
McCready et al.26) 2 94 0 94 3.4% 5.00 [0.24, 102.77]
Herrera Siklódy et al.19) 9 24 2 27 9.2% 5.06 [1.21, 21.16]
Spitzer et al.27) 6 388 5 151 10.9% 0.47 [0.14, 1.51]
Tivig et al.16) 5 209 6 211 10.9% 0.84 [0.26, 2.71]
 
Total (95% CI)  1368 1250 100.0% 1.04 [0.55, 1.93]
Total events 53 50
Heterogeneity: Tau2=0.57; Chi2=21.86, df=11 (p<0.03); I2=50% 
Test for overall effect: Z=0.11 (p=0.91)
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a repeat procedure is triggered by AF recurrence, which is 
more common after CPVI. Tivig et al.16) reported that low-
power MEA ablation reduced the need for repeat procedures 
compared to use of standard RF ablation; low-power ablation 
to a defined lesional depth (using appropriate generator set-
tings) may prevent extensive tissue injury. The success of MEA 
is explained by the high-level lesional integrity afforded by use 
of circumferential ablation catheters compared to the point-
by-point ablation of 3D systems. Improved lesional integrity 
reduces the opportunities for reconnection of trigger foci. Al-
though 3D systems allow precise visualization of the positions 
of mapping and ablation catheters, construction of such com-
plex maps is associated with a steep learning curve, compro-
mising success rates in newer centers.
Of the various complications associated with the MEA and 
CPVI procedures, thromboembolic events were the most 
common and the risk of such events was somewhat higher af-
ter MEA, significantly different from the risk after CPVI. 
However, sub-group analysis by follow-up period revealed that 
the risk of such events tended to be slightly lower upon longer-
term follow-up after MEA, in contrast to the higher incidence 
observed during the acute period (1–2 days) after the proce-
dure. Deneke et al.20) evaluated the clinical consequences and 
longer-term characteristics of lesions in patients with acutely 
detected ischemic embolic lesions after catheter ablation of AF. 
Only acute lesions of maximum diameters >10 mm were de-
tected on longer-term follow-up MRI; 94% of lesions resolved 
without identifiable scar formation. The mechanisms by which 
silent brain injuries are caused remain unclear; blood clots, air, 
tissue, or fat, may be in play. Alternatively, such injuries may be 
produced upon sheath manipulation prior to left atrial cathe-
terization, or by ablation per se. Asymptomatic cerebral MRI 
lesions may trigger subclinical deterioration, but no patient 
had any detectable neurological deficit immediately after abla-
tion or on follow-up evaluation performed by an experienced 
neurologist.20) Also, no AF ablation study revealed any connec-
tion between development of silent ischemic MRI lesions and 
adverse neuropsychological outcomes.32,33) Although the de-
velopment of thromboembolic events after AF ablation is of 
concern, no relationship between such events and an adverse 
outcome or deterioration in neuropsychological performance 
was substantiated in any trial. Further long-term studies are 
needed to evaluate patient outcomes. The catheter type used 
during MEA was associated with development of thrombo-
embolic events. Recently, Verma et al.34) described several ways 
by which the development of silent intracranial embolisms 
may be minimized via catheter manipulation and appropriate 
electrode use with maintenance of good success rates.
Conclusions
Upon meta-analysis, multielectrode ablation used to treat 
AF afforded beneficial reductions in all of procedural, fluoro-
scopic, and RF application times, but the outcomes in terms of 
acute procedural success, AF recurrence and the need for re-
peat procedure were comparable to those of traditional treat-
ment, CPVI. Although the thromboembolism risk at 1–2 days 
post-procedure was slightly elevated, the long-term safety pro-
file of MEA was comparable to that of CPVI, indicating that 
MEA benefits patients with AF when skilled physicians per-
form the procedure carefully. Further, larger, well-organized 
randomized trials combined with analysis of cost-effectiveness 
are needed.
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Supplementary Fig. 1. Forest plot for stratified relative risks (RR) of thromboembolic events between multielectrode catheter ablation 
(MEA) and conventional pulmonary vein isolation (CPVI) by follow-up duration. CI: confidence interval.
Study or subgroup
MEA CPVI
Weight
Risk ratio       Risk ratio
Events Total Events Total M-H, fixed, 95% CI        M-H, fixed, 95% CI
7.2.1 1–2 days       
Gaita et al.21) 14 36 3 36 34.6%  4.67 [1.47, 14.86]
McCready et al.26)  2 94 0 94 5.8%  5.00 [0.24, 102.77]
Herrera Siklódy et al.19)  9 24 2 27 21.7% 5.06 [1.21, 21.16]
Subtotal (95% CI) 154 157 62.1% 4.84 [2.04, 11.47]
Total events 25 5
Heterogeneity: Chi2=0.01, df=2 (p=1.00); I2=0% 
Test for overall effect: Z=3.58 (p=0.0003)
7.2.2 ≥6 months
Bittner et al.17) 1 40 1 40 11.5% 1.00 [0.06, 15.44]
De Greef et al.24) 0 79 0 82 Not estimable
Deneke et al.20) 2 11 1 3 18.1% 0.55 [0.07, 4.16]
Gal et al.25) 0 230 0 230 Not estimable
Spitzer et al.27) 2 388 0 151 8.3% 1.95 [0.09, 40.46]
Subtotal (95% CI) 748 506 37.9% 0.99 [0.23, 4.19]
Total events 5 2
Heterogeneity: Chi2=0.52, df=2 (p=0.77); I2=0% 
Test for overall effect: Z=0.01 (p=0.99)
Total (95% CI)  902 663 100.0% 3.38 [1.67, 6.85]
Total events 30 7
Heterogeneity: Chi2=4.65, df=5 (p=0.46); I2=0% 
Test for overall effect: Z=3.38 (p=0.0007)
Test for subgroup differences: Chi2=3.41, df=1 (p=0.06); I2=70.7% 
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